• Mitochondrial Calcium Signaling Suppresses Ferroptosis in Ca

  2026-04-21

  This study uncovers a direct mechanistic link between mitochondrial calcium uptake and the suppression of ferroptotic cell death in cancer, mediated by acetylation-dependent regulation of GPX4 activity. These findings highlight new opportunities to target mitochondrial metabolism and epigenetic regulation in cancer therapy.

• Vancomycin Hydrochloride: Precision Control in Antibiotic Re

  2026-04-21

  Discover how Vancomycin hydrochloride elevates glycopeptide antibacterial agent research with advanced assay applications, mechanistic insights, and evidence-based protocols. This article uniquely bridges PKPD modeling to practical antibiotic resistance workflows.

• Autophagy–Metastasis Signature Predicts CRC Prognosis and Im

  2026-04-20

  Bai et al. (2026) developed and validated a prognostic signature for colorectal cancer by integrating autophagy- and liver metastasis-associated gene expression using bulk and single-cell transcriptomic data. This signature not only outperformed traditional risk factors in predicting patient outcomes but also illuminated mechanisms linking autophagy, metastatic progression, and immune evasion—informing future biomarker and therapeutic strategies.

• EdU Flow Cytometry Assay Kits (Cy5): Precision in S-Phase De

  2026-04-20

  The EdU Flow Cytometry Assay Kits (Cy5) empower researchers to quantify cell proliferation with outstanding sensitivity and workflow simplicity. Their click chemistry-based detection of DNA synthesis sets a new standard for multiplexed, reproducible cell cycle analysis across oncology, wound healing, and genotoxicity research.

• Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal S

  2026-04-19

  Bafilomycin A1 empowers researchers to dissect lysosomal function, intracellular pH regulation, and proteostasis with nanomolar precision. This guide delivers actionable workflows, advanced troubleshooting, and contextualizes new insights from centriolar satellite research to optimize your use of this gold-standard V-ATPase inhibitor.

• Trichostatin A: HDAC Inhibitor Optimizing Epigenetic Workflo

  2026-04-18

  Trichostatin A (TSA) from APExBIO is a benchmark HDAC inhibitor, empowering researchers to induce robust histone acetylation, cell cycle arrest, and antiproliferative effects in cancer models. This guide details stepwise protocols, advanced applications, and troubleshooting strategies to maximize TSA’s impact in epigenetic and oncology research.

• Bradykinin B2 Receptor Modulation of Ileal Peristalsis: Key

  2026-04-17

  This study demonstrates that bradykinin inhibits peristaltic reflexes in the guinea pig ileum via B2 receptor activation, a novel mechanistic insight for gastrointestinal motility research. The findings clarify receptor subtype roles and provide a pharmacological basis for future studies targeting bradykinin pathways in gut physiology.

• LGK-974: Benchmark PORCN Inhibitor for Wnt Pathway Research

  2026-04-16

  LGK-974 empowers researchers with nanomolar-precision inhibition of the Wnt signaling pathway, enabling robust modeling of Wnt-driven cancer and β-catenin transcriptional activity. Explore how this potent PORCN inhibitor, supplied by APExBIO, streamlines experimental workflows and delivers reproducible results in both in vitro and in vivo systems.

• AI-Derived Prognostic Signature Enhances HCC Risk Stratifica

  2026-04-15

  This large-scale, multi-center study introduces a consensus artificial intelligence-driven prognostic signature (CAIPS) for hepatocellular carcinoma (HCC), surpassing existing clinical and molecular models in risk prediction. CAIPS integrates machine learning with multi-omics analysis, revealing actionable biomarkers and candidate therapeutics, advancing precision oncology for HCC.

• DiscoveryProbe Protease Inhibitor Library: Enabling Mechanis

  2026-04-14

  Explore how the DiscoveryProbe Protease Inhibitor Library empowers next-generation oncology and apoptosis assays through mechanistic insight into protease inhibition. Uncover unique strategies for target validation and high content screening that set this resource apart.

• A-769662: Redefining AMPK Activation in Energy Stress Resear

  2026-04-13

  Explore the unique, dual-action profile of A-769662 as an AMPK activator and proteasome modulator. This article offers an advanced analysis, integrating new mechanistic insights for researchers investigating energy metabolism regulation and metabolic disease.

• Strategic Caspase Inhibition: Advancing Inflammation & Cance

  2026-04-13

  This article explores the mechanistic and translational value of Z-WEHD-FMK, a potent irreversible caspase inhibitor, for dissecting pyroptosis, apoptosis, and inflammatory signaling in disease models. Anchored by recent primary research on HOXC8 and caspase-1 in lung tumorigenesis, we examine experimental best practices, competitive differentiation, and future directions for researchers leveraging Z-WEHD-FMK in cell biology and infectious disease research.

• Doxorubicin in Translational Oncology: Mechanism to Impact

  2026-04-12

  This thought-leadership article explores how Doxorubicin (Adriamycin), a cornerstone chemotherapeutic agent, is reshaping translational cancer research. We dissect its mechanistic underpinnings, highlight state-of-the-art validation using high-content phenotypic screening, and provide strategic guidance for researchers navigating efficacy, resistance, and toxicity. Drawing on recent evidence and APExBIO’s Doxorubicin (A3966) as a benchmark tool, the discussion bridges molecular insight with actionable protocol guidance and future-facing perspectives.

• Cy5 maleimide (non-sulfonated): Protocols for Thiol Labeling

  2026-04-12

  Cy5 maleimide (non-sulfonated) addresses the need for site-specific, covalent fluorescent labeling of proteins and peptides through cysteine residues. It is optimized for workflows requiring high-purity thiol-reactive dyes and precise probe conjugation but is not recommended where water solubility or non-thiol selectivity is required.

• Cisapride (R 51619): Best Practices in Cardiac Electrophysio

  2026-04-11

  Cisapride (R 51619) empowers researchers to dissect cardiac electrophysiology and cardiotoxicity with precision, especially in high-content phenotypic screening using iPSC-derived cardiomyocytes. This article delivers actionable protocols, troubleshooting insights, and comparative analysis to maximize data quality and translational relevance for cardiac arrhythmia research.

15983 records 1/1066 page Next 12345 下5页 Last page